Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

What happened: Genmab shares rose to a record high after positive data for its experimental cancer drug petosemtamab. Jefferies described the results as a "hat trick." Key numbers: The headline reports the drug slashed risk of death by 50%. Why it matters: Jefferies called the data positive, and the stock reaction was a move to a record high. Market: +0.2% today ($287.07), +27.2% YTD, 0.3x vol — as of 18:47 UTC Verified: Q3_2026 (Oct 30) revenue $17.3B vs $17.3B est; next print ~Jan 29 Coverage: 3 outlets in 24h

Genmab shares rose to a record high after positive data for its experimental cancer drug petosemtamab. Jefferies described the results as a "hat trick."

Jefferies called the data positive, and the stock reaction was a move to a record high. Market: +0.2% today ($287.07), +27.2% YTD, 0.3x vol — as of 18:47 UTC Verified: Q3_2026 (Oct 30) revenue $17.3B vs $17.3B est; next print ~Jan 29